Focus: AviadoBio is a UK-based public biotech company specializing in gene therapies for neurodegenerative diseases, with a focused pipeline in rare neurological indications. The company operates at an early clinical stage with limited commercial scale.
Profile data last refreshed 5h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow AviadoBio to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for AviadoBio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from AviadoBio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
AviadoBio broadens vMiX gene silencing licence with King’s College London - Pharmaceutical Technology
AviadoBio broadens vMiX gene silencing licence with King’s College London Pharmaceutical Technology
Biopharma bites: Novo sheds 400 Indiana jobs, Alltrna nears clinical milestone, and more from Astellas, Sanofi - FirstWord Pharma
Biopharma bites: Novo sheds 400 Indiana jobs, Alltrna nears clinical milestone, and more from Astellas, Sanofi FirstWord Pharma
AviadoBio Advances AVB-101 Gene Therapy Program and Initiates Fourth Dose-Escalation Cohort of Phase 1/2 ASPIRE-FTD Trial - Business Wire
AviadoBio Advances AVB-101 Gene Therapy Program and Initiates Fourth Dose-Escalation Cohort of Phase 1/2 ASPIRE-FTD Trial Business Wire
8-K Filing: ClearPoint Neuro, Inc. (CLPT) (CIK 0001285550) — EX-99.2
EX-99.2
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company